Mr. Quang Pham
Chairman and CEO
Mr. Pham is a biopharmaceutical entrepreneur with over 20 years of experience in founding, financing, and growing companies. Prior to founding Espero, he started Lathian Systems, an innovative company that provided online data and marketing services to pharmaceutical and biotech companies.
Mr. Jeff Cole
President and CFO
Mr. Cole has over 23 years of experience in finance, business development and commercial operations at public and privately held companies. This includes more than 15 years in the pharmaceutical industry holding various senior executive roles at companies such as Valeant Pharmaceuticals (NYSE: VRX), Solco Healthcare US, MarcasUSA, and Legacy Pharmaceuticals. His positions at Valeant included CFO North America, VP of Corporate Development, and General Manager of the US Specialty Division.
Dr. Pascal Druzgala
Senior Vice President,
Research & Development
Dr. Druzgala was a co-founder of Armetheon, where he served as Senior Vice President, Research & Development. He was in charge of all discovery programs. Dr. Druzgala was also a co-founder and board member of Optivia Biotechnology, and a co-founder of ARYx Therapeutics (NASDAQ:ARYX), where he served as senior VP and CSO from 1997 to 2011 as well as chairman of the scientific advisory board.
Dr. Druzgala received a Pharm.D. degree in 1978 from the University of Montpellier, France, and then went on to earn a diplôme d’études approfondies degree (DEA) at the European Institute of Industrial Pharmaceutical Sciences (IPIM), also in Montpellier, France. Dr. Druzgala later graduated in 1985 from the University of Florida with a doctorate in medicinal chemistry. He completed his post-doctorate work at the Center for Drug Design and Discovery at the University of Florida, where he first experimented with various drug discovery programs utilizing retrometabolic techniques. These techniques, pioneered by Dr. Nicholas Bodor in the late 1970s, are the basis for the research into enhanced safety for Espero BioPharma’s clinical-stage drug candidate: tecarfarin.
Mr. Andrew Lam
Vice President, Product Development
Mr. Lam is currently Vice President of Product Development at Espero BioPharma, where he leads the CMC development and pharmaceutical operations. Prior to joining Espero, Mr. Lam has more than 24 years of experience in pharmaceutical product development, with a primary focus in the development of controlled release products.
Prior to Exelixis, Mr. Lam served as Senior Director of Liquid OROS® Technology Development at ALZA, a Johnson & Johnson company, where he developed the liquid delivery technology for poorly soluble compounds and advanced a number of new molecular entities to human studies. During his tenure at ALZA, Mr. Lam held numerous positions in pharmaceutics research, formulation, process scale-up and development, and served as project team leader for the development of three commercialized products from early compound development to product launch. Andrew received the 2002 Johnson Medal, the most distinguished award at Johnson & Johnson, for development of CONCERTA®, a multi-billion dollar product for attention deficit hyperactive disorder. As pharmaceutical development leader, Mr. Lam filed 29 INDs, 3 NDAs, 2 MAAs and 1 JNDA, and managed the post-approval changes of marketed products.
Andrew is an inventor on 20 issued US patents and 4 additional US published patent applications. He holds a BS in Chemical Engineering from the University of California, Davis.